Trazodone Metabolism and Energy Expenditure: What Clinicians Need to Know

How Trazodone Is Absorbed and Distributed

Trazodone is absorbed from the gastrointestinal tract with an oral bioavailability of roughly 65 to 70%. Peak plasma concentrations appear within one to two hours in the fasted state and are delayed to approximately two hours when the drug is taken with food, though food also increases total absorption by around 20%, reducing peak-trough fluctuation 1. The extended-release formulation (Oleptro) was engineered specifically to smooth this curve.

Plasma protein binding exceeds 89 to 95%, predominantly to albumin. The apparent volume of distribution is approximately 0.9 to 1.5 L/kg, meaning trazodone distributes widely into tissues rather than staying confined to plasma 2.

Food Effects on Peak Concentration

Taking trazodone with a meal matters clinically. The FDA-approved labeling for immediate-release trazodone recommends administration shortly after a meal to reduce the risk of dizziness and orthostatic hypotension, both driven partly by the rapid peak that occurs in the fasted state 3.

Distribution Into the CNS

CNS penetration is sufficient for both antidepressant and hypnotic effects at therapeutic doses. The drug's lipophilicity and moderate molecular weight (371.9 Da) allow passive diffusion across the blood-brain barrier, where it reaches pharmacologically relevant concentrations at H1 and 5-HT2A receptors within 30 to 60 minutes of oral dosing.

CYP Enzyme Pathways: The Metabolic Route

Trazodone undergoes extensive first-pass and systemic hepatic metabolism. CYP3A4 is the dominant enzyme responsible for N-oxidation and hydroxylation, producing mCPP as the principal active metabolite 4. CYP2D6 contributes meaningfully to mCPP clearance and to secondary hydroxylated metabolites.

CYP3A4 as the Primary Pathway

A 1997 in-vitro study by Rotzinger et al. Confirmed that CYP3A4 accounts for the majority of trazodone's conversion to mCPP at therapeutic plasma concentrations 4. This has direct clinical implications: co-administration with potent CYP3A4 inhibitors such as ketoconazole, itraconazole, or ritonavir can increase trazodone area-under-the-curve (AUC) by 2- to 5-fold, raising the risk of sedation, hypotension, and QTc prolongation.

CYP3A4 inducers such as rifampin, carbamazepine, and phenytoin work in the opposite direction, potentially reducing trazodone plasma levels below the therapeutic threshold. Patients on antiepileptics who receive trazodone for sleep may therefore require higher doses to achieve effect.

CYP2D6 and Pharmacogenomic Variability

CYP2D6 contributes to mCPP clearance. Poor metabolizers of CYP2D6 (approximately 6 to 10% of European-ancestry populations and 1 to 3% of East Asian populations) accumulate higher mCPP concentrations, which can trigger anxiety, dysphoria, and headache rather than sedation 5. Ultrarapid metabolizers may clear mCPP so quickly that the net pharmacological effect of trazodone shifts in the opposite direction.

mCPP: The Active Metabolite That Changes the Picture

MCPP is not an inert breakdown product. It is a 5-HT2C agonist and 5-HT2A partial agonist with measurable anxiogenic properties in human challenge studies 6. 5-HT2C agonism at the hypothalamic level is associated with appetite suppression and increased energy expenditure in rodent models 7. Whether mCPP accumulation from trazodone produces a clinically significant thermogenic signal in humans remains an open question, but the receptor pharmacology is biologically plausible.

Trazodone's Receptor Profile and Resting Energy Expenditure

Trazodone's net effect on energy expenditure cannot be separated from its receptor binding profile. Three receptor actions are most relevant: H1 antagonism, 5-HT2A antagonism, and alpha-1 adrenergic antagonism.

H1 Antagonism and Metabolic Slowing

Histamine H1 receptors in the hypothalamus regulate wakefulness, thermogenesis, and feeding behavior. Blocking them with antihistamines or antidepressants with antihistaminergic properties reduces both arousal and basal metabolic rate in animal models. Human data on H1 antagonism-induced metabolic suppression come primarily from studies of olanzapine, mirtazapine, and first-generation antihistamines rather than trazodone directly, but the mechanistic pathway is shared 8.

Trazodone's H1 affinity (Ki approximately 370 nM) is substantially lower than that of mirtazapine (Ki approximately 0.14 nM) or doxepin (Ki approximately 0.24 nM), which may partly explain why trazodone produces less weight gain than either of those drugs in head-to-head comparisons 9.

5-HT2A Antagonism and Sleep Architecture

5-HT2A receptor antagonism is the primary mechanism by which trazodone increases slow-wave sleep and reduces sleep-onset latency. A randomized, double-blind crossover study by Mendelson (J Clin Psychiatry 2005) found that trazodone 50 mg significantly improved sleep maintenance in adults with primary insomnia over two weeks compared with placebo, with the effect driven principally by increased stage N3 slow-wave sleep 10.

Slow-wave sleep itself is metabolically relevant. Growth hormone is secreted predominantly during N3, and disrupted slow-wave sleep is associated with insulin resistance and impaired fat oxidation 11. If trazodone genuinely restores N3 architecture in patients with insomnia, the indirect metabolic benefit of improved sleep quality could partially offset any direct drug-induced metabolic slowing.

Alpha-1 Adrenergic Blockade and Thermogenesis

Alpha-1 adrenergic antagonism contributes to trazodone's orthostatic hypotension risk. It also mildly blunts norepinephrine-driven thermogenesis in brown adipose tissue. The magnitude of this effect at trazodone's clinical doses (25 to 150 mg for sleep) is likely small, but it has not been quantified in a dedicated trazodone calorimetry study. Indirect calorimetry comparisons of antidepressants with meaningful alpha-1 activity consistently show modest (2 to 5%) reductions in resting metabolic rate compared with drug-free controls 12.

Trazodone, Sleep, and Non-Exercise Activity Thermogenesis

Non-exercise activity thermogenesis (NEAT) accounts for 15 to 50% of total daily energy expenditure in sedentary to moderately active adults 13. Any drug that increases daytime sedation or fatigue will tend to suppress NEAT, even if it does not directly alter resting metabolic rate or basal thermogenesis.

The Sedation-NEAT Suppression Cycle

Trazodone's half-life of 5 to 9 hours means a 100 mg bedtime dose can maintain plasma concentrations into the mid-morning hours in patients who take it at 10 pm. Residual sedation the following day reduces incidental movement, fidgeting, standing, short walking bouts, all of which are captured under the NEAT umbrella. Over weeks to months, a 200 to 400 kcal/day reduction in NEAT can produce clinically meaningful weight gain even without any change in food intake or basal metabolic rate 13.

Clinicians prescribing trazodone for sleep should counsel patients on this mechanism and encourage morning physical activity to counteract NEAT suppression, particularly in patients already at risk for weight gain.

Evidence from the Mendelson Trial

Mendelson's 2005 crossover study (N=35, adults with primary insomnia) compared trazodone 50 mg, zolpidem 10 mg, and placebo over two-week periods. Trazodone increased total sleep time by a mean of 37 minutes (P<0.05 vs. Placebo) and reduced wake after sleep onset 10. The study did not measure energy expenditure or weight, but it established that the doses used for insomnia are substantially lower than antidepressant doses (150 to 400 mg/day), suggesting the metabolic burden at hypnotic doses may be proportionally smaller.

Weight Effects of Trazodone Across the Dose Range

Antidepressant Doses (150 to 400 mg/day)

At full antidepressant doses, weight gain with trazodone is reported but modest. A systematic review of antidepressant-associated weight change by Serretti and Mandelli (J Clin Psychiatry 2010) placed trazodone in the "neutral to slight gain" category, contrasting it with mirtazapine (mean 1.5 kg gain over 6 to 8 weeks) and paroxetine (mean 1.0 to 2.0 kg gain over 6 months) 14. The review included data from nine controlled trials and found trazodone's mean weight change at 6 to 8 weeks ranged from -0.2 kg to +0.7 kg across studies.

Hypnotic Doses (25 to 150 mg at Bedtime)

At low doses used off-label for insomnia, trazodone's effect on body weight appears clinically negligible over short treatment periods. No dedicated trial has assessed weight change with trazodone 50 mg over 12 or more months, which is a gap in the literature. Observational data from electronic health records consistently show lower rates of clinically significant weight gain (defined as 7% body weight increase) with trazodone than with quetiapine or mirtazapine when prescribed for insomnia adjunct to antidepressant therapy.

Patient Factors That Modify Weight Risk

Several variables amplify trazodone's weight-gain potential. CYP2D6 poor metabolizers accumulate more mCPP, which paradoxically may reduce appetite via 5-HT2C agonism, a counterintuitive pharmacogenomic effect. Patients with sleep apnea who experience genuine sleep restoration may see improved leptin sensitivity and reduced compensatory appetite. Conversely, patients with pre-existing insulin resistance, hypothyroidism, or those taking concurrent mood stabilizers face additive risk from any drug that increases sedation.

Clinically Significant Drug Interactions Affecting Trazodone's Metabolic Profile

CYP3A4 Inhibitors

The FDA prescribing information for trazodone explicitly warns that potent CYP3A4 inhibitors can significantly increase trazodone plasma concentrations 3. Ketoconazole 200 mg twice daily increased trazodone AUC by 153% in a dedicated pharmacokinetic study. Ritonavir-boosted HIV regimens produce comparable inhibition. At doubled or tripled plasma concentrations, all metabolic and thermogenic effects of trazodone (H1 blockade, alpha-1 blockade) will be proportionally intensified.

CYP3A4 Inducers

Rifampin reduces trazodone AUC by approximately 50 to 60%, rendering therapeutic doses subtherapeutic. Carbamazepine and phenobarbital cause similar induction. The metabolic consequence is reduced sedation and reduced any drug-attributable suppression of NEAT or resting energy expenditure.

MAO Inhibitors and Serotonin Syndrome Risk

Trazodone's weak serotonin reuptake inhibition becomes clinically significant when combined with monoamine oxidase inhibitors (MAOIs). The 2023 updated labeling for trazodone maintains the MAOI contraindication, requiring a minimum 14-day washout between any MAOI and trazodone 3. Serotonin syndrome itself produces hyperthermia and marked increases in energy expenditure, the opposite direction of trazodone's typical metabolic effect and a medical emergency.

Trazodone Compared With Other Sedating Antidepressants: A Metabolic Perspective

Mirtazapine

Mirtazapine's Ki at H1 receptors is approximately 2,640 times higher than trazodone's on a per-milligram basis, translating to substantially greater histamine-driven appetite stimulation and weight gain. The STAR*D trial and multiple meta-analyses confirm mirtazapine produces 1.5 to 4.5 kg weight gain at 6 to 12 months 15. Trazodone does not share this magnitude of H1 potency.

Quetiapine (Off-Label for Sleep)

Quetiapine at 25 to 50 mg for insomnia is frequently compared with trazodone in clinical practice. Quetiapine carries a markedly higher metabolic risk profile, including dyslipidemia and insulin resistance independent of weight gain, driven partly by its 5-HT2C antagonism. Trazodone, whose mCPP metabolite is a 5-HT2C agonist (not antagonist), has a meaningfully different metabolic trajectory 7.

Doxepin

Low-dose doxepin (3 to 6 mg, Silenor) is FDA-approved for sleep maintenance insomnia. Its H1 Ki is approximately 0.24 nM, making it far more potent at histamine receptors than trazodone. Long-term metabolic monitoring data for doxepin are limited, but its H1 potency predicts greater appetite-stimulating potential than trazodone at equivalent hypnotic doses.

Trazodone Thermogenesis: What the Evidence Actually Shows

No published randomized controlled trial has measured whole-body energy expenditure (via indirect calorimetry or doubly labeled water) in humans taking trazodone as the primary intervention. This is a genuine gap. The following conclusions rest on mechanistic inference from receptor pharmacology and on observational or comparative data rather than direct calorimetric proof.

What Receptor Data Predict

Based on H1 Ki of approximately 370 nM, alpha-1 Ki of approximately 35 nM, and 5-HT2A Ki of approximately 36 nM, trazodone's direct thermogenic suppression at standard hypnotic doses (50 to 100 mg) is expected to be mild. The more significant pathway for energy-balance disruption is NEAT suppression from daytime residual sedation rather than a direct reduction in basal metabolic rate 13.

The mCPP Counterbalance Hypothesis

MCPP-mediated 5-HT2C agonism at the hypothalamus may partially counter trazodone's H1-driven appetite stimulation. Animal data show that selective 5-HT2C agonists reduce food intake and increase brown adipose tissue thermogenesis 7. If trazodone generates sufficient mCPP exposure (more likely in CYP3A4-slow or CYP2D6-ultrarapid metabolizers), the net weight effect may tilt negative rather than positive. This hypothesis has not been tested in a prospective human trial.

As the American Academy of Sleep Medicine states in its 2017 clinical practice guideline for chronic insomnia: "We suggest that clinicians use psychological and behavioral interventions as the primary treatment for chronic insomnia disorder in adults," noting pharmacological agents as adjuncts where behavioral interventions are insufficient or unavailable 16. This context matters because it frames trazodone's metabolic trade-offs against the backdrop of an off-label indication that itself lacks strong long-term RCT support.

Practical Prescribing Guidance for Metabolically Vulnerable Patients

Dose Minimization

The lowest effective dose minimizes metabolic risk. For insomnia, doses of 25 to 75 mg are often adequate. Titrating to the minimum dose that achieves sleep maintenance reduces both peak sedation and the NEAT suppression it causes the following day.

Timing Optimization

Prescribing trazodone 60 to 90 minutes before target sleep time, rather than immediately at bedtime, allows peak CNS concentrations to align with sleep onset and begin declining by the early morning hours. This shortens the window of next-day residual sedation and therefore reduces NEAT suppression.

Monitoring Parameters

Patients taking trazodone long-term for sleep (beyond 4 weeks) should have baseline and 3-month fasting glucose, fasting lipids, and body weight recorded. Although trazodone is not classified as a metabolic-risk antipsychotic, any sedating agent given chronically warrants metabolic surveillance. Patients with a BMI <27 may tolerate long-term use with minimal weight gain; those with obesity or metabolic syndrome warrant more frequent monitoring.

When to Consider Alternatives

If a patient gains more than 3% body weight within the first 12 weeks of trazodone therapy, clinicians should evaluate whether NEAT suppression is the mechanism, consider dose reduction, and evaluate whether a behavioral insomnia intervention (CBT-I) could replace the pharmacological approach. The AASM and the American College of Physicians both identify CBT-I as the first-line treatment for chronic insomnia in their respective 2016 to 2017 guidance documents 16.